The link between atrial fibrillation and stroke in women

Women's Health

Volumn 7, Issue 3, 2011, Pages 375-382

  Madias, Christopher ^a   Trohman, Richard G ^a  

^a RUSH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

anticoagulation; atrial fibrillation; stroke; thromboembolism; women

Indexed keywords

APIXABAN; DABIGATRAN; ESTROGEN; RIVAROXABAN; THROMBIN INHIBITOR; VON WILLEBRAND FACTOR; WARFARIN; XIMELAGATRAN;

ANTICOAGULANT THERAPY; ATHEROSCLEROSIS; BLEEDING; BRAIN ISCHEMIA; CORONARY ARTERY DISEASE; DISEASE ASSOCIATION; EMBOLISM; ENDOTHELIAL DYSFUNCTION; FEMALE; HEART ATRIUM FIBRILLATION; HEART FAILURE; HORMONE SUBSTITUTION; HUMAN; HYPERTENSION; INTERNATIONAL NORMALIZED RATIO; LIVER TOXICITY; PERIPHERAL VASCULAR DISEASE; POSTMENOPAUSE; REVIEW; RISK FACTOR; RISK REDUCTION; SELF CARE; SEX DIFFERENCE; STROKE; THROMBOEMBOLISM; THYROTOXICOSIS; TRANSIENT ISCHEMIC ATTACK;

ANTICOAGULANTS; ATRIAL FIBRILLATION; FEMALE; HEMORRHAGE; HORMONE REPLACEMENT THERAPY; HUMANS; RISK FACTORS; SEX FACTORS; STROKE; THROMBOEMBOLISM; WARFARIN;

EID: 79957572267     PISSN: 17455057     EISSN: 17455065     Source Type: Journal    
DOI: 10.2217/whe.11.29     Document Type: Review

References (60)

1. Volgman AS, Manankil MF, Mookherjee D, Trohman RG: Women with atrial fibrillation: greater risk, less attention. Gend. Med. 6, 419-432 (2009).
2. Fuster V, Ryden LE, Cannom DS et al.: ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation - executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (writing committee to revise the 2001 guidelines for the management of patients with atrial fibrillation). J. Am. Coll. Cardiol. 48, 854-906 (2006).
3. Singer DE, Albers GW, Dalen JE et al.: Antithrombotic therapy in atrial fibrillation: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 133, 546S-592S (2008).
4. Stroke Risk in Atrial Fibrillation Working Group: Independent predictors of stroke in patients with atrial fibrillation: a systematic review. Neurology 69, 546-554 (2007).
5. Stroke Risk in Atrial Fibrillation Working Group: Comparison of 12 risk stratification schemes to predict stroke in patients with nonvalvular atrial fibrillation. Stroke 39, 1901-1910 (2008).
6. Cabin HS, Clubb KS, Hall C, Perlmutter RA, Feinstein AR: Risk for systemic embolization of atrial fibrillation without mitral stenosis. Am. J. Cardiol. 65, 1112-1116 (1990).
7. Boysen G, Nyboe J, Appleyard M et al.: Stroke incidence and risk factors for stroke in Copenhagen, Denmark. Stroke 19, 1345-1353 (1988).
8. Novello P, Ajmar G, Bianchini D et al.: Ischemic stroke and atrial fibrillation. A clinical study. Ital. J. Neurol. Sci. 14, 571-576 (1993).
9. Aronow WS, Gutstein H, Hsieh FY: Risk factors for thromboembolic stroke in elderly patients with chronic atrial fibrillation. Am. J. Cardiol. 63, 366-367 (1989).
10. Petersen P, Kastrup J, Helweg-Larsen S, Boysen G, Godtfredsen J: Risk factors for thromboembolic complications in chronic atrial fibrillation. The Copenhagen AFASAK study. Arch. Intern. Med. 150, 819-821 (1990).
11. Hughes M, Lip GY: Stroke and thromboembolism in atrial fibrillation: a systematic review of stroke risk factors, risk stratification schema and cost effectiveness data. Thromb. Haemost. 99, 295-304 (2008). Systematic review of stroke risk factors in atrial fibrillation, including gender.
12. Wang TJ, Massaro JM, Levy D et al.: A risk score for predicting stroke or death in individuals with new-onset atrial fibrillation in the community: the Framingham Heart Study. JAMA 290, 1049-1056 (2003). Derivation of the Framingham risk score for stroke in atrial fibrillation. Female gender was identified as an independent predictor of stroke.
13. Hart RG, Pearce LA, Rothbart RM, McAnulty JH, Asinger RW, Halperin JL: Stroke with intermittent atrial fibrillation: incidence and predictors during aspirin therapy. Stroke Prevention in Atrial Fibrillation Investigators. J. Am. Coll. Cardiol. 35, 183-187 (2000).
14. Hart RG, Pearce LA, McBride R, Rothbart RM, Asinger RW: Factors associated with ischemic stroke during aspirin therapy in atrial fibrillation: analysis of 2012 participants in the SPAF I-III clinical trials. The Stroke Prevention in Atrial Fibrillation (SPAF) Investigators. Stroke 30, 1223-1229 (1999). Analysis of participants given aspirin alone or in combination with low, inefficacious doses of warfarin in the Stroke Prevention in Atrial Fibrillation I-III trials. Female gender proved to be one of five independent predictors of stroke.
15. van Latum JC, Koudstaal PJ, Venables GS, van Gijn J, Kappelle LJ, Algra A: Predictors of major vascular events in patients with a transient ischemic attack or minor ischemic stroke and with nonrheumatic atrial fibrillation. European Atrial Fibrillation Trial (EAFT) Study Group. Stroke 26, 801-806 (1995).
16. Aronow WS, Ahn C, Kronzon I, Gutstein H: Risk factors for new thromboembolic stroke in patients > or = 62 years of age with chronic atrial fibrillation. Am. J. Cardiol. 82, 119-121 (1998).
17. Nakagami H, Yamamoto K, Ikeda U, Mitsuhashi T, Goto T, Shimada K: Mitral regurgitation reduces the risk of stroke in patients with nonrheumatic atrial fibrillation. Am. Heart J. 136, 528-532 (1998).
18. The SPAF III Writing Committee for the Stroke Prevention in Atrial Fibrillation Investigators: Patients with nonvalvular atrial fibrillation at low risk of stroke during treatment with aspirin: Stroke Prevention in Atrial Fibrillation III Study. The SPAF III Writing Committee for the Stroke Prevention in Atrial Fibrillation Investigators. J. Am. Geriat. Soc. 279, 1273-1277 (1998).
19. Inoue H, Atarashi H: Risk factors for thromboembolism in patients with paroxysmal atrial fibrillation. Am. J. Cardiol. 86, 852-855 (2000).
20. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials. Arch. Intern. Med. 154, 1449-1457 (1994). Data were pooled from five randomized trials assessing the effectiveness of warfarin or aspirin versus control in patients with atrial fibrillation. Stroke risk was not significantly elevated in women.
21. Friberg J, Scharling H, Gadsboll N, Truelsen T, Jensen GB: Comparison of the impact of atrial fibrillation on the risk of stroke and cardiovascular death in women versus men (the Copenhagen City Heart Study). Am. J. Cardiol. 94, 889-894 (2004).
22. Fang MC, Singer DE, Chang Y et al.: Gender differences in the risk of ischemic stroke and peripheral embolism in atrial fibrillation: the Anticoagulation and Risk Factors in Atrial Fibrillation (ATRIA) study. Circulation 112, 1687-1691 (2005). Gender analysis of the Anticoagulation and Risk Factors in Atrial Fibrillation (ATRIA) cohort reveals female sex as an independent risk factor for thromboembolism in atrial fibrillation.
23. Reeves MJ, Bushnell CD, Howard G et al.: Sex differences in stroke: epidemiology, clinical presentation, medical care, and outcomes. Lancet Neurol. 7, 915-926 (2008).
24. Conway DS, Heeringa J, Van Der Kuip DA et al.: Atrial fibrillation and the prothrombotic state in the elderly: the Rotterdam Study. Stroke 34, 413-417 (2003).
25. Wang TD, Chen WJ, Su SS et al.: Increased levels of tissue plasminogen activator antigen and factor VIII activity in nonvalvular atrial fibrillation: relation to predictors of thromboembolism. J. Cardiovasc. Electrophysiol. 12, 877-884 (2001).
26. Wieberdink RG, van Schie MC, Koudstaal PJ et al.: High von Willebrand factor levels increase the risk of stroke: the Rotterdam study. Stroke 41, 2151-2156 (2010).
27. Wassertheil-Smoller S, Hendrix SL, Limacher M et al.: Effect of estrogen plus progestin on stroke in postmenopausal women: the Women's Health Initiative: a randomized trial. JAMA 289, 2673-2684 (2003).
28. Gomberg-Maitland M, Wenger NK, Feyzi J et al.: Anticoagulation in women with non-valvular atrial fibrillation in the stroke prevention using an oral thrombin inhibitor (SPORTIF) trials. Eur. Heart J. 27, 1947-1953 (2006).
29. Squizzato A, Gerdes VE, Brandjes DP, Buller HR, Stam J: Thyroid diseases and cerebrovascular disease. Stroke 36, 2302-2310 (2005).
30. Sheu JJ, Kang JH, Lin HC, Lin HC: Hyperthyroidism and risk of ischemic stroke in young adults: a 5-year follow-up study. Stroke 41, 961-966 (2010).
31. Frost L, Vestergaard P, Mosekilde L: Hyperthyroidism and risk of atrial fibrillation or flutter: a population-based study. Arch. Intern. Med. 164, 1675-1678 (2004).
32. Dagres N, Nieuwlaat R, Vardas PE et al.: Gender-related differences in presentation, treatment, and outcome of patients with atrial fibrillation in Europe: a report from the Euro Heart Survey on Atrial Fibrillation. J. Am. Coll. Cardiol. 49, 572-577 (2007). Gender analysis of the Euro Heart Survey revealed women with atrial fibrillation have more comorbidities and a higher chance of stroke.
33. Humphries KH, Kerr CR, Connolly SJ et al.: New-onset atrial fibrillation: sex differences in presentation, treatment, and outcome. Circulation 103, 2365-2370 (2001).
34. Towfighi A, Saver JL, Engelhardt R, Ovbiagele B: A midlife stroke surge among women in the United States. Neurology 69, 1898-1904 (2007).
35. Daly C, Clemens F, Lopez Sendon JL et al.: Gender differences in the management and clinical outcome of stable angina. Circulation 113, 490-498 (2006).
36. Mosca L, Merz NB, Blumenthal RS et al.: Opportunity for intervention to achieve American Heart Association guidelines for optimal lipid levels in high-risk women in a managed care setting. Circulation 111, 488-493 (2005).
37. Mosca L, Linfante AH, Benjamin EJ et al.: National study of physician awareness and adherence to cardiovascular disease prevention guidelines. Circulation 111, 499-510 (2005).
38. Lip GY, Frison L, Grind M: Effect of hypertension on anticoagulated patients with atrial fibrillation. Eur. Heart J. 28, 752-759 (2007).
39. Arima H, Hart RG, Colman S et al.: Perindopril-based blood pressure-lowering reduces major vascular events in patients with atrial fibrillation and prior stroke or transient ischemic attack. Stroke 36, 2164-2169 (2005).
40. Almdal T, Scharling H, Jensen JS, Vestergaard H: The independent effect of Type 2 diabetes mellitus on ischemic heart disease, stroke, and death: a population-based study of 13,000 men and women with 20 years of follow-up. Arch. Intern. Med. 164, 1422-1426 (2004).
41. Ford ES, Giles WH, Dietz WH: Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA 287, 356-359 (2002).
42. Hart RG, Pearce LA, Aguilar MI: Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann. Intern. Med. 146, 857-867 (2007).
43. Go AS, Hylek EM, Chang Y et al.: Anticoagulation therapy for stroke prevention in atrial fibrillation: how well do randomized trials translate into clinical practice? JAMA 290, 2685-2692 (2003).
44. Wyse DG, Waldo AL, DiMarco JP et al.: A comparison of rate control and rhythm control in patients with atrial fibrillation. N. Engl. J. Med. 347, 1825-1833 (2002).
45. Poli D, Antonucci E, Grifoni E, Abbate R, Gensini GF, Prisco D: Gender differences in stroke risk of atrial fibrillation patients on oral anticoagulant treatment. Thromb. Haemost. 101, 938-942 (2009).
46. Kapral MK, Fang J, Hill MD et al.: Sex differences in stroke care and outcomes: results from the Registry of the Canadian Stroke Network. Stroke 36, 809-814 (2005).
47. Heneghan C, Alonso-Coello P, Garcia-Alamino JM, Perera R, Meats E, Glasziou P: Self-monitoring of oral anticoagulation: a systematic review and meta-analysis. Lancet 367, 404-411 (2006).
48. Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW, Radford MJ: Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA 285, 2864-2870 (2001).
49. Lip GY, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ: Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the Euro Heart Survey on Atrial Fibrillation. Chest 137, 263-272 (2010). Development of the Birmingham 2009 risk schema, cardiac failure or dysfunction, hypertension, age ≥75 (double point), diabetes, previous stroke (double point), vascular disease, age 65-74 and female sex.
50. Lip GY, Frison L, Halperin JL, Lane DA: Identifying patients at high risk for stroke despite anticoagulation: a comparison of contemporary stroke risk stratification schemes in an anticoagulated atrial fibrillation cohort. Stroke 41, 2731-2738 (2010).
51. Van Staa TP, Setakis E, Di Tanna GL, Lane DA, Lip GY: A comparison of risk stratification schemes for stroke in 79,884 atrial fibrillation patients in general practice. J. Thromb. Haemost. 9, 39-48 (2011).
52. Olesen JB, Lip GY, Hansen ML et al.: Validation of risk stratification schemes for predicting stroke and thromboembolism in patients with atrial fibrillation: nationwide cohort study. BMJ 342, D124 (2011). Stroke risk associated with a specific risk stratification score depends on the risk factors composing the score. Cardiac failure or dysfunction, hypertension, age ≥75 (double point), diabetes, previous stroke (double point), vascular disease, age 65-74 and female sex, performed better than congestive heart failure, hypertension, age, diabetes, previous stroke (double point) in predicting patients at a high risk of stroke.
53. Connolly SJ, Ezekowitz MD, Yusuf S et al.: Dabigatran versus warfarin in patients with atrial fibrillation. N. Engl. J. Med. 361, 1139-1151 (2009). In patients with atrial fibrillation, dabigatran compared with warfarin was associated with lower rates of stroke and systemic embolism but similar rates of major hemorrhage.
54. Connolly SJ, Eikelboom J, Joyner C et al.: Apixaban in patients with atrial fibrillation. N. Engl. J. Med. 364, 806-817 (2011).
55. Gensch C, Hoppe U, Bohm M, Laufs U: Late-breaking clinical trials presented at the American Heart Association Congress in Chicago 2010. Clin. Res. Cardiol. 100(1), 1-9 (2010).
56. Ezekowitz MD, Aikens TH, Brown A, Ellis Z: The evolving field of stroke prevention in patients with atrial fibrillation. Stroke 41, S17-S20 (2010).
57. Giorgi MA, Cohen Arazi HN, Gonzalez CD, Di Girolamo G: Changing anticoagulant paradigms for atrial fibrillation: dabigatran, apixaban and rivaroxaban. Expert Opin. Pharmacother. 12, 567-577 (2011).
58. Wann LS, Curtis AB, January CT et al.: 2011 ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation (updating the 2006 guideline): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 123, 104-123 (2011).
59. CEJA Report B - I-90: Gender disparities in clinical decision-making www.ama-assn.org/ama1/pub/upload/mm/code-medical-ethics/9122a.pdf (Accessed 12 January 2011)
60. National Collaborating Centre for Chronic Conditions: Atrial fibrillation. National clinical guideline for management in primary and secondary care. Royal College of Physicians, UK (2006) http://guidance.nice.org. uk/CG36/Guidance/pdf/English (Accessed 12 January 2011)